AbbVie Announces $1.4B Manufacturing Campus in North Carolina
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy ABBV?
Source: seekingalpha
- Major Investment Announcement: AbbVie has revealed plans to construct a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, with a total investment of $1.4 billion, marking its first significant investment in the state and expected to greatly enhance local economic vitality.
- Job Creation Impact: The project is anticipated to create 734 jobs in engineering, manufacturing, and other roles over the next four years, while also adding over 2,000 construction jobs during the building phase, thereby further stimulating the local job market.
- Technological Innovation: The state-of-the-art facility will leverage artificial intelligence to support the production of AbbVie's immunology, neuroscience, and oncology medicines, enhancing production efficiency and product quality, which will strengthen the company's competitive position in the biopharmaceutical sector.
- Long-term Strategic Investment: This investment is part of AbbVie's broader plan to spend over $100 billion on R&D and capital investments in the U.S., demonstrating the company's strong confidence in future growth and commitment to the domestic market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 197.690
Low
223.00
Averages
252.00
High
289.00
Current: 197.690
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie Q1 Earnings Beat Expectations with Strong Revenue Growth
- Significant Revenue Growth: AbbVie's Q1 revenue reached $15 billion, reflecting a 12.4% year-over-year increase, exceeding market expectations by $280 million, indicating strong performance in the immunology sector.
- Immunology Product Performance: Global net revenues from the immunology portfolio were $7.290 billion, up 16.4%, with Skyrizi generating $4.483 billion, Rinvoq $2.119 billion, and Humira $688 million, demonstrating the driving force of new products in the company's growth.
- Adjusted EPS Guidance Raised: AbbVie raised its adjusted diluted EPS guidance for 2026 from $13.96-$14.16 to $14.08-$14.28, despite accounting for a $0.41 per share impact from acquisition-related expenses, reflecting the company's confidence in future performance.
- Competitive Market Advantage: AbbVie's Rinvoq outperformed Humira in a head-to-head study for rheumatoid arthritis, further solidifying its competitive position in the immunology market and indicating potential for future growth.
See More
AbbVie Q1 Earnings Expected to Show Recovery
- Earnings Growth Expectation: AbbVie is projected to report Q1 EPS growth of 8.5% year-over-year to $2.67, with revenue expected at $14.72 billion, reflecting a 10.3% increase, aligning with the company's own guidance and indicating a recovery in profitability.
- Long-Term Growth Drivers: Analysts believe that strong performances from Skyrizi and Rinvoq will offset the decline from Humira, with long-term earnings projections indicating a compound annual growth rate (CAGR) in the upper single digits, suggesting stable growth for the company moving forward.
- Sales Forecast: Management anticipates a total sales growth of 9.5% for the year, with net revenues around $67 billion, an adjusted gross margin exceeding 84%, and an adjusted operating margin ratio of approximately 48.5%, further solidifying the company's market position.
- Dividend Growth Recovery: Analysts noted that AbbVie's recent annual dividend increase of 5.48% suggests a stabilization in growth following a recent slowdown, enhancing investor confidence in the company's future prospects.
See More
AbbVie Stock Fluctuates as Immunology Drugs Offset Humira Decline
- Stock Volatility: AbbVie's stock experienced significant fluctuations on Wednesday, primarily due to the strong performance of its immunology drugs partially offsetting the ongoing decline of Humira, demonstrating the company's flexibility in product portfolio management.
- Immunology Drug Performance: Despite the decline in Humira sales, AbbVie's immunology drugs continue to perform well, indicating success in new drug development and marketing, which enhances investor confidence in future growth.
- Humira Sales Decline: The ongoing decline in Humira sales puts pressure on AbbVie's overall performance; however, the company mitigates this impact through a diversified product line, showcasing its ability to respond to market challenges.
- Market Reaction: Investors reacted positively to AbbVie's immunology drug performance, and despite the challenges posed by Humira, the market remains optimistic about the company's future growth potential, reflecting recognition of its strategic direction.
See More
AbbVie Raises Full-Year Earnings Outlook Amid Strong Drug Performance
- Earnings Beat: AbbVie reported $15 billion in revenue for Q1 2026, reflecting a ~12% year-over-year growth that exceeded consensus estimates by $280 million, showcasing the strong performance of its newer drugs Skyrizi and Rinvoq, which offset declines from Humira.
- Significant Drug Contributions: Skyrizi and Rinvoq generated $4.5 billion and $2.1 billion in global sales, respectively, with year-over-year growth rates of ~31% and ~23%, enhancing the company's competitive position and laying a solid foundation for future revenue growth.
- Humira Sales Decline: Once the world's best-selling drug, Humira's revenue fell to $688 million, down ~39% year-over-year, primarily due to competition from biosimilars, indicating the need for AbbVie to accelerate the market introduction of new products to stabilize revenue.
- Profitability Analysis: AbbVie's adjusted gross margin and operating margin stood at 83.6% and 40.8%, down from 84.1% and 42.3% in the prior year, while adjusted diluted EPS of $2.65, despite an ~8% year-over-year increase, missed consensus by $0.02, reflecting ongoing profitability pressures.
See More
AbbVie Earnings Analysis and Growth Outlook
- Earnings Performance: AbbVie reported a non-GAAP EPS of $2.65, missing expectations by $0.02, while revenue reached $15 billion, exceeding market forecasts by $280 million, indicating resilience in revenue growth despite EPS shortfall.
- Product Competitiveness: AbbVie's Rinvoq outperformed Humira in a head-to-head study for rheumatoid arthritis, enhancing the competitiveness of its portfolio and potentially driving future market share growth in a lucrative therapeutic area.
- Investment Rating: Analysts have upgraded AbbVie’s rating, although with caveats, reflecting ongoing market confidence in its growth potential while cautioning investors to remain aware of potential risks that could impact performance.
- Dividends and Potential: AbbVie’s dividend policy, combined with its ability to renew its product portfolio, showcases significant growth potential, appealing to investors seeking stable returns in a dynamic pharmaceutical landscape.
See More
AbbVie Reports Strong Quarterly Earnings Driven by Immunology Drugs
- New Drug Sales Surge: AbbVie's immunology drugs Skyrizi and Rinvoq drove better-than-expected quarterly revenue and profit, with Skyrizi achieving $4.48 billion in sales for Q1, a 30.9% increase year-over-year, surpassing Wall Street's $4.41 billion estimate, indicating strong market acceptance and profitability of new products.
- Humira Sales Decline: Following Humira's loss of U.S. patent exclusivity in 2023, global sales fell 38.6% to $688 million, slightly missing analysts' expectations of $696.5 million, reflecting the challenges and competitive pressures the company faces during its transition.
- Neuroscience Business Outperformance: AbbVie's neuroscience portfolio saw a 26% revenue increase to $2.88 billion, with Botox Therapeutic sales exceeding $1 billion for the first time in a quarter, showcasing strong demand and market potential in this sector.
- Full-Year Earnings Guidance Raised: The company raised its full-year adjusted earnings forecast to a range of $14.08 to $14.28 per share from the previous $13.96 to $14.16, indicating management's confidence in future performance and positive outlook on market demand.
See More
AbbVie Q1 Earnings Beat Expectations with Strong Revenue Growth
- Significant Revenue Growth: AbbVie's Q1 revenue reached $15 billion, reflecting a 12.4% year-over-year increase, exceeding market expectations by $280 million, indicating strong performance in the immunology sector.
- Immunology Product Performance: Global net revenues from the immunology portfolio were $7.290 billion, up 16.4%, with Skyrizi generating $4.483 billion, Rinvoq $2.119 billion, and Humira $688 million, demonstrating the driving force of new products in the company's growth.
- Adjusted EPS Guidance Raised: AbbVie raised its adjusted diluted EPS guidance for 2026 from $13.96-$14.16 to $14.08-$14.28, despite accounting for a $0.41 per share impact from acquisition-related expenses, reflecting the company's confidence in future performance.
- Competitive Market Advantage: AbbVie's Rinvoq outperformed Humira in a head-to-head study for rheumatoid arthritis, further solidifying its competitive position in the immunology market and indicating potential for future growth.
See More
AbbVie Q1 Earnings Expected to Show Recovery
- Earnings Growth Expectation: AbbVie is projected to report Q1 EPS growth of 8.5% year-over-year to $2.67, with revenue expected at $14.72 billion, reflecting a 10.3% increase, aligning with the company's own guidance and indicating a recovery in profitability.
- Long-Term Growth Drivers: Analysts believe that strong performances from Skyrizi and Rinvoq will offset the decline from Humira, with long-term earnings projections indicating a compound annual growth rate (CAGR) in the upper single digits, suggesting stable growth for the company moving forward.
- Sales Forecast: Management anticipates a total sales growth of 9.5% for the year, with net revenues around $67 billion, an adjusted gross margin exceeding 84%, and an adjusted operating margin ratio of approximately 48.5%, further solidifying the company's market position.
- Dividend Growth Recovery: Analysts noted that AbbVie's recent annual dividend increase of 5.48% suggests a stabilization in growth following a recent slowdown, enhancing investor confidence in the company's future prospects.
See More
AbbVie Stock Fluctuates as Immunology Drugs Offset Humira Decline
- Stock Volatility: AbbVie's stock experienced significant fluctuations on Wednesday, primarily due to the strong performance of its immunology drugs partially offsetting the ongoing decline of Humira, demonstrating the company's flexibility in product portfolio management.
- Immunology Drug Performance: Despite the decline in Humira sales, AbbVie's immunology drugs continue to perform well, indicating success in new drug development and marketing, which enhances investor confidence in future growth.
- Humira Sales Decline: The ongoing decline in Humira sales puts pressure on AbbVie's overall performance; however, the company mitigates this impact through a diversified product line, showcasing its ability to respond to market challenges.
- Market Reaction: Investors reacted positively to AbbVie's immunology drug performance, and despite the challenges posed by Humira, the market remains optimistic about the company's future growth potential, reflecting recognition of its strategic direction.
See More
AbbVie Raises Full-Year Earnings Outlook Amid Strong Drug Performance
- Earnings Beat: AbbVie reported $15 billion in revenue for Q1 2026, reflecting a ~12% year-over-year growth that exceeded consensus estimates by $280 million, showcasing the strong performance of its newer drugs Skyrizi and Rinvoq, which offset declines from Humira.
- Significant Drug Contributions: Skyrizi and Rinvoq generated $4.5 billion and $2.1 billion in global sales, respectively, with year-over-year growth rates of ~31% and ~23%, enhancing the company's competitive position and laying a solid foundation for future revenue growth.
- Humira Sales Decline: Once the world's best-selling drug, Humira's revenue fell to $688 million, down ~39% year-over-year, primarily due to competition from biosimilars, indicating the need for AbbVie to accelerate the market introduction of new products to stabilize revenue.
- Profitability Analysis: AbbVie's adjusted gross margin and operating margin stood at 83.6% and 40.8%, down from 84.1% and 42.3% in the prior year, while adjusted diluted EPS of $2.65, despite an ~8% year-over-year increase, missed consensus by $0.02, reflecting ongoing profitability pressures.
See More
AbbVie Earnings Analysis and Growth Outlook
- Earnings Performance: AbbVie reported a non-GAAP EPS of $2.65, missing expectations by $0.02, while revenue reached $15 billion, exceeding market forecasts by $280 million, indicating resilience in revenue growth despite EPS shortfall.
- Product Competitiveness: AbbVie's Rinvoq outperformed Humira in a head-to-head study for rheumatoid arthritis, enhancing the competitiveness of its portfolio and potentially driving future market share growth in a lucrative therapeutic area.
- Investment Rating: Analysts have upgraded AbbVie’s rating, although with caveats, reflecting ongoing market confidence in its growth potential while cautioning investors to remain aware of potential risks that could impact performance.
- Dividends and Potential: AbbVie’s dividend policy, combined with its ability to renew its product portfolio, showcases significant growth potential, appealing to investors seeking stable returns in a dynamic pharmaceutical landscape.
See More
AbbVie Reports Strong Quarterly Earnings Driven by Immunology Drugs
- New Drug Sales Surge: AbbVie's immunology drugs Skyrizi and Rinvoq drove better-than-expected quarterly revenue and profit, with Skyrizi achieving $4.48 billion in sales for Q1, a 30.9% increase year-over-year, surpassing Wall Street's $4.41 billion estimate, indicating strong market acceptance and profitability of new products.
- Humira Sales Decline: Following Humira's loss of U.S. patent exclusivity in 2023, global sales fell 38.6% to $688 million, slightly missing analysts' expectations of $696.5 million, reflecting the challenges and competitive pressures the company faces during its transition.
- Neuroscience Business Outperformance: AbbVie's neuroscience portfolio saw a 26% revenue increase to $2.88 billion, with Botox Therapeutic sales exceeding $1 billion for the first time in a quarter, showcasing strong demand and market potential in this sector.
- Full-Year Earnings Guidance Raised: The company raised its full-year adjusted earnings forecast to a range of $14.08 to $14.28 per share from the previous $13.96 to $14.16, indicating management's confidence in future performance and positive outlook on market demand.
See More
